Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $41.00 Price Target at The Goldman Sachs Group

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target upped by equities research analysts at The Goldman Sachs Group from $36.00 to $41.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target points to a potential downside of 12.11% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Trading Up 0.3 %

Shares of TARS stock opened at $46.65 on Friday. Tarsus Pharmaceuticals has a twelve month low of $15.60 and a twelve month high of $52.99. The company has a current ratio of 7.03, a quick ratio of 6.99 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average is $37.55 and its two-hundred day moving average is $32.43. The company has a market capitalization of $1.77 billion, a P/E ratio of -12.24 and a beta of 1.00.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Assenagon Asset Management S.A. acquired a new position in shares of Tarsus Pharmaceuticals in the second quarter worth $28,904,000. Healthcare of Ontario Pension Plan Trust Fund raised its stake in Tarsus Pharmaceuticals by 1,113.5% in the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 898,000 shares of the company’s stock valued at $32,642,000 after purchasing an additional 824,000 shares during the last quarter. Jennison Associates LLC boosted its stake in shares of Tarsus Pharmaceuticals by 47.2% during the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after purchasing an additional 698,712 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Tarsus Pharmaceuticals in the first quarter valued at approximately $12,640,000. Finally, Millennium Management LLC lifted its stake in shares of Tarsus Pharmaceuticals by 1,259.3% during the second quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after buying an additional 322,942 shares during the period. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.